Veille Pharma
Follow
19.5K views | +0 today
Veille Pharma
Responsable des études chez VIGIEPHARMA. Mes posts n'engagent que moi. http://www.vigiepharma.fr/
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

Pharmacie : McKesson et Celesio créent le leader mondial des services de santé

Pharmacie : McKesson et Celesio créent le leader mondial des services de santé | Veille Pharma | Scoop.it
C’est le plus gros mariage depuis des années dans la distribution pharmaceutique. Le géant américain McKesson a réussi à trouver un accord...
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Popular medical apps share physician names with pharmaceutical advertisers

Popular medical apps share physician names with pharmaceutical advertisers | Veille Pharma | Scoop.it
Epocrates, Medscape, and other popular free medical apps share the identifiable information of healthcare professionals with pharmaceutical advertisers
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Joseph Jimenez describes how drug companies can meet the world's dramatically changing health-care needs. - Project Syndicate

Joseph Jimenez describes how drug companies can meet the world's dramatically changing health-care needs. - Project Syndicate | Veille Pharma | Scoop.it
Demographic trends, shifting patterns of disease, and strained public funding are placing new burdens on health-care systems.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Évaluer l’information sur Internet et prescrire des ressources aux patients | Portail Internet et santé

Évaluer l’information sur Internet et prescrire des ressources aux patients | Portail Internet et santé | Veille Pharma | Scoop.it
Le modèle centré sur le patient qui semble s’imposer dans la formation médicale, met l’accent sur l’importance de prendre en compte la vision du patient, de l’amener à participer au processus de soins et souligne le rôle que joue la communication...
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Les outils de social media listening : état des lieux du marché

Les outils de social media listening : état des lieux du marché | Veille Pharma | Scoop.it
Un temps réservé aux groupes les plus importants, aux directeurs de la communication les plus zélés, l’écoute des conversations en ligne et la surveillance des publications sur le web est devenue une...
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ViewPoints: Stratospheric Sovaldi analyst tips $5 billion sales for Gilead Sciences' Hep C drug in
2014

ViewPoints: Stratospheric Sovaldi  analyst tips $5 billion sales for Gilead Sciences' Hep C drug in<br/>2014 | Veille Pharma | Scoop.it

Regular FirstWord Pharma PLUS readers may not be surprised to hear that a leading pharmaceutical equity analyst – International Strategy & Investment's Mark Schoenebaum – has suggested that Gilead Sciences' hepatitis C treatment Sovaldi could generate global sales of $5 billion in 2014, its first year on the market.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ChangePain : GRUNENTHAL investit la e-health

ChangePain : GRUNENTHAL investit la e-health | Veille Pharma | Scoop.it

Les Laboratoires Grünenthal mettent à la disposition des professionnels de santé une application complète autour de la prise en charge de la douleu

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions — NEJM

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions — NEJM | Veille Pharma | Scoop.it

The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

EMA recommends 81 medicines for marketing authorisation in 2013

EMA recommends 81 medicines for marketing authorisation in 2013 | Veille Pharma | Scoop.it

In 2013, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended 81* medicines for human use for marketing authorisation, compared with 57 in 2012.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Doctors Get Fewer Perks, Free Lunches - Pharma Marketing Network Forums

Doctors Get Fewer Perks, Free Lunches - Pharma Marketing Network Forums | Veille Pharma | Scoop.it
Doctors Get Fewer Perks, Free Lunches Physician Marketing, Sales, & Education
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Should journals stop publishing research funded by the drug industry? | BMJ

Should journals stop publishing research funded by the drug industry? | BMJ | Veille Pharma | Scoop.it

The BMJ no longer publishes research funded by tobacco companies. Richard Smith and Peter Gøtzsche say that research funded by drug companies is also flawed and published to encourage sales, but Trish Groves says that the industries are fundamentally different and that moves are afoot to increase integrity

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Une vaste cyberattaque affecte de nombreux objets connectés !

Une vaste cyberattaque affecte de nombreux objets connectés ! | Veille Pharma | Scoop.it
La première cyberattaque d'objets connectés a été découverte il y a quelques jours par la société de sécurité californienne Proofpoint. En effet, des pirates
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Only just the beginning of the end of hepatitis C : The Lancet

Only just the beginning of the end of hepatitis C. By - The Lancet
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

e-Santé 2014 : conférence pour décrypter les nouveaux enjeux

e-Santé 2014 : conférence pour décrypter les nouveaux enjeux | Veille Pharma | Scoop.it
Le 24 mars prochain, CCM Benchmark organise une grande conférence "e-Santé 2014". Présentation. Face au développement de l’e-santé et de toutes ces nouvelles tendances (Msanté, Quantified self, E-r...
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Digital Health In 2014: The Imperative Of Connectivity

Digital Health In 2014: The Imperative Of Connectivity | Veille Pharma | Scoop.it
Build it and they will come. I sense that this may be a guiding principle to digital health. Build a sexy device or a cool app and the democratization of healthcare will magically appear.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Surprising Findings for Lenalidomide Maintenance in Updated IFM 2005-02 Analysis

Surprising Findings for Lenalidomide Maintenance in Updated IFM 2005-02 Analysis | Veille Pharma | Scoop.it

A new analysis of the multiple myeloma Intergroupe Francophone du Myelome (IFM) 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival.1 This is possibly attributed to the shorter survival time after first disease progression than is observed in patients receiving placebo, the investigators suggested.

more...
No comment yet.
Rescooped by Alexandre DUBOIS from Pharma
Scoop.it!

Mobile is not optional if you want to reach rheumatologists

Mobile is not optional if you want to reach rheumatologists | Veille Pharma | Scoop.it

43% of rheumatologists report they use four digital devices on a regular basis (desktop, laptop, tablet, phone). 32% report they use three devices and 18% report they use two devices.

 

Only 7% are only using one device

 

Among devices used for professional purposes, rheumatologists report they use their smartphone the most often (41%) and their smartphone has the greatest influence (30%) on their practice and clinical decision-making.


Via Andrew Spong
more...
Andrew Spong's curator insight, January 23, 2014 1:11 AM

...or, indeed, any other specialty. As I discovered at EULAR last year, however, when rheumatologists do go for digital, they go all the way!

Scooped by Alexandre DUBOIS
Scoop.it!

KOL vs DOL, Part I: the emergence of Digital Opinion Leaders in Healthcare

KOL vs DOL, Part I: the emergence of Digital Opinion Leaders in Healthcare | Veille Pharma | Scoop.it

Once upon a time, opinion leaders in all aspects of life were people that had spent considerable time on a subject, through academic study or hands-on experience, or both. Such individuals had the authority that came from having witnessed all possible outcomes of different theories and behaviors but, as Albert Einstein said: “the permanence of an expert in a subject area is the greatest obstacle to the advancement of the subject”. Revolutions in thinking were slow to occur.

more...
Brian Bernstein's curator insight, January 28, 2014 7:50 AM

Makes on think this little  thing called the Internet is taking off.

Scooped by Alexandre DUBOIS
Scoop.it!

Un nouveau numéro sur les usages d’Internet en santé | Portail Internet et santé

Un nouveau numéro sur les usages d’Internet en santé | Portail Internet et santé | Veille Pharma | Scoop.it
La Revue internationale de communication sociale et publique vous propose un numéro thématique qui s’intéresse aux usages santé d’Internet
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

FirstWord Lists The drugs that will shape 2014

FirstWord Lists  The drugs that will shape 2014 | Veille Pharma | Scoop.it
FirstWord Pharma - Gain Access to the Information You Need Track the Companies,
Products, and Regulatory Areas of Most Interest to You
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

L’ANSM propose des aides à la prescription des NACO | Le Quotidien du Medecin

L’ANSM propose des aides à la prescription des NACO | Le Quotidien du Medecin | Veille Pharma | Scoop.it

Dans son dernier bulletin « Vigilances » daté de janvier 2014, l’Agence nationale de sécurité du médicament et des produits de santé met à disposition des professionels de santé des tableaux téléchargeables afin d’aider les prescripteurs à s’approprier l’usage des nouveaux anticoagulants

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Digital recruitment for clinical trials - PMLiVE

Digital recruitment for clinical trials - PMLiVE | Veille Pharma | Scoop.it

There is strong industry interest in exploring how digital channels could improve clinical trial recruitment rates - a costly and time-consuming issue for pharma.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Pharma Marketing Blog: Pharma Sales Jobs Take A(nother) Tumble! Digital's Slow But Relentless Impact.

Pharma Marketing Blog: Pharma Sales Jobs Take A(nother) Tumble! Digital's Slow But Relentless Impact. | Veille Pharma | Scoop.it

Two stories in today's Wall Street Journal caught my attention. The first article reported that Eli Lilly will lay off 30% of its U.S. salesforce (see here). Why? Generics, of course, was mentioned first. But if you read on, you will find this tidbit:

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study | Veille Pharma | Scoop.it
Key points

 

Pomalidomide plus low-dose dexamethasone significantly improved PFS versus pomalidomide alone in relapsed and refractory multiple myeloma

Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who had received multiple prior therapies

more...
No comment yet.